* Strong early data point with 25% conversion rate for Doro in D2C * .
Tove Christiansson, currently Head of the Assistive Tech Business Area at MedCap, will take on the r...
Redeye comments on decision by the VGR Regional Board regarding Millennium and the modular alternati...
ChargePanels månatliga omsättning har ökat med 18,3 respektive 34,4 procent under september och okto...
The change from a 510k back to its original De Novo pathway is mostly a non-event for the case.
SyntheticMR redovisade ett svagt tredje kvartal där omsättningen sjönk med 7 procent och resultatet ...
* Rail and Kvalitetsbygg sold, while we see... * ..
Today, Monday, 1 December, is the ex-rights date for the preferential rights issue, marking the firs...
Redeye provides an update following Mindark’s Q3 2025 report.
Will lower financial expenses by SEK 2m per year We estimate ND/EBITDA of ~1.
Redeye comments on MindArk’s Q3 results, which showed figures in line with estimates, apart from sli...
* An organic decline of 3% in Q3 * We cut sales estimates by 4-2% for '26e-'27e * Positioned for a m...
Redeye comments on FluoGuide’s Q3 2025 report. The company has posted a busy news flow in recent mon...
* Encouraging ACV growth and margins * Small sales revisions, but '26e-'27e EBIT up 29-28% on lower ...
Top Picks comments on a significant development that fundamentally changes one of our investment the...
